i3 Consult Press Releases

Biotechnology R&D spending reached $45.7 billion by FY2016, this represented a 12% increase from the previous financial year. This was the seventh consecutive year that biotech companies increased their cumulative R&D spending and has led to a booming CRO market, expected to nearly double in a six-year period from $34 billion in 2014 to $59.42 billion in 2020. Commensurate with this market growth and as a “knock-on” effect, there has been a notable emergence of niche or specialised CROs as well as a proliferation of mergers and acquisitions as   companies attempt to solidify their position in a highly competitive industry. The key CRO players continue to maintain their service focus on recruiting, developing, and retaining top performing sites. Recent hikes in clinical development programs in the last five years has caused a disparity between the growing number of studies and that of the clinical sites willing to conduct studies. This disparity has been noted as early as

At i3 Consult we have been successful in ensuring that a biotechnology client of ours retained a significant portion of funds upon initiating their highly successful IPO. Our client was a university based incubator company preparing for its IPO. In order to do this, they needed a comprehensive evaluation of the protein biomarker marketplace, including sales trends, competitive activity, client needs analysis and analogous case studies of competitors. i3 Consult provided a final valuation of investment funding, business angels and contingency VC funding. This begs the question, how was this possible? Below is outlined our approach to the project. Our Approach Focus groups/structured teleconference meetings consisting of 5 to 10 team members each from a cross-section of the Biotech company’s value chain were conducted to brainstorm on the critical success factors that will procure a greater market share. As a further refinement strategy, surveys of closed research instrument desi

Africa has been battling with AIDS for over 3 decades now and many measures have been put in place to combat and slow the rate of HIV/AIDS infections. Although the continent is home to about 15.2 percent of the world's population, more than two-thirds of the total infected worldwide – some 35 million people – are of African ethnicity, of whom 15 million have become fatalities. According to a recent UNAIDS report [1] , East and Southern Africa is the region most affected by HIV in the world where it is home to the largest number of people living with HIV, estimated to be 19.4 million. Countries in North Africa and the Horn of Africa have significantly lower prevalence rates, as their populations typically engage in fewer high-risk lifestyle patterns that have been implicated in the virus' spread in Sub-Saharan Africa. In Western Africa region there are moderate levels of HIV infections, with the lowest rate being in Senegal and the highest in Nigeria, which has the second large